ARDM Aradigm Corporation

5.45
+0.30  (6%)
Previous Close 5.15
Open 5.19
Price To book -13.63
Market Cap 82360825
Shares 15,112,078
Volume 341,179
Short Ratio 0.46
Av. Daily Volume 447,181

SEC filingsSee all SEC filings

  1. 8-K - Current report 171026822
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171025942
  3. 8-K - Current report 17955786
  4. SC 13G - Statement of acquisition of beneficial ownership by individuals 17904598
  5. 8-K - Current report 17892076

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approval granted July 16, 2009.
Sumavel
Migraine
PDUFA date under priority review January 26, 2018. Phase 3 data released December 1, 2016. One of two trials met primary endpoint.
Linhaliq (Pulmaquin)
Non-cystic fibrosis bronchiectasis (non-CF BE).

Latest News

  1. Aradigm (ARDM) Shares March Higher, Can It Continue?
  2. New Research Coverage Highlights Aradigm, Social Reality Inc, Rentech, PayPal, JPMorgan Chase, and Helios and Matheson Analytics ­Consolidated Revenues, Company Growth, and Expectations
  3. Aradigm Regains Compliance with NASDAQ Listing Requirements
  4. Can Aradigm Corporation (ARDM) Improve Your Portfolio Returns?
  5. Aradigm, NDA for Linhaliq Accepted by FDA With Priority Review, Catalyst and Pipeline Review
  6. Corporate News Blog - Aradigm Announces FDA Acceptance of Priority Review Status for its NDA for Linhaliq
  7. Aradigm Announces FDA Acceptance of NDA for Linhaliq with Priority Review Status
  8. Aradigm to Present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26
  9. Aradigm to Host KOL Call on Infection Management in Non-Cystic Fibrosis Bronchiectasis Patients
  10. Aradigm Announces Upcoming Data Presentations in Non-Cystic Fibrosis Bronchiectasis at the European Respiratory Society (ERS) 2017 Annual Congress
  11. Aradigm Awarded NIH Grant to Investigate the Treatment of Pulmonary Non-Tuberculous Mycobacterial (PNTM) Infections with Linhaliq
  12. Aradigm posts 2Q profit
  13. Aradigm Announces Second Quarter 2017 Financial Results
  14. Aradigm Submits New Drug Application (NDA) to FDA for U.S. Marketing Approval of Linhaliq in Non-Cystic Fibrosis Bronchiectasis
  15. Aradigm reports 1Q loss
  16. Aradigm Announces First Quarter 2017 Financial Results
  17. Aradigm Announces Fourth Quarter 2016 and Full Year Financial Results
  18. Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2017 on February 13
  19. Aradigm to Present at 9th Annual Biotech Showcase Conference on January 9